821 reports of this reaction
5.0% of all APALUTAMIDE reports
#4 most reported adverse reaction
HOT FLUSH is the #4 most commonly reported adverse reaction for APALUTAMIDE, manufactured by Janssen Products, LP. There are 821 FDA adverse event reports linking APALUTAMIDE to HOT FLUSH. This represents approximately 5.0% of all 16,304 adverse event reports for this drug.
Patients taking APALUTAMIDE who experience hot flush should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOT FLUSH is moderately reported among APALUTAMIDE users, representing a notable but not dominant share of adverse events.
In addition to hot flush, the following adverse reactions have been reported for APALUTAMIDE:
The following drugs have also been linked to hot flush in FDA adverse event reports:
HOT FLUSH has been reported as an adverse event in 821 FDA reports for APALUTAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOT FLUSH accounts for approximately 5.0% of all adverse event reports for APALUTAMIDE, making it a notable side effect.
If you experience hot flush while taking APALUTAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.